SCHEMBL24256858

SCHEMBL24256858

COc1ccc(CCNC(=O)c2sc3nc(C)c4c(c3c2N)CCC4)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.62
LMNA P02545 3/20 0.62
HPGD P15428 1/20 0.62
MAPT P10636 5/20 0.53
KDM4E B2RXH2 3/20 0.53
ATM Q13315 2/20 0.53
HTT P42858 2/20 0.53
NPC1 O15118 1/20 0.53
USP28 Q96RU2 4/20 0.53
USP25 Q9UHP3 4/20 0.53
NAMPT P43490 2/20 0.53
ALDH1A1 P00352 3/20 0.52
GAA P10253 2/20 0.52
GLA P06280 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
KMT2A Q03164 1/20 0.51
CHRM4 P08173 4/20 0.50
RAB9A P51151 1/20 0.50
FLT1 P17948 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256612 0.89 MTOR (0.60) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24256709 0.88 MTOR (0.61) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24256678 0.88 LMNA (0.67) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24256707 0.87 MTOR (0.58) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24592798 0.79 USP25 (0.75) USP28USP25
SCHEMBL24256847 0.78 USP25 (0.69) MTORUSP28USP25
SCHEMBL24256669 0.77 MTOR (0.48) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL26780707 0.77 KDM4E (0.51) MTORLMNAHPGDMAPTKDM4E
SCHEMBL13568228 0.76 LMNA (1.00) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL26780405 0.76 USP25 (0.55) MAPTKDM4EUSP28USP25ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 MTOR 2191/4885SMN1; SMN2 1921/4885LMNA 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.